Unicycive Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Unicycive Therapeutics (NASDAQ:UNCY) reported Q2 losses of $(0.29) per share, beating the analyst consensus estimate of $(0.34) by 14.71%. However, this represents a 20.83% increase in losses compared to the same period last year.

August 14, 2023 | 9:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Unicycive Therapeutics reported better than expected Q2 losses, but the losses increased compared to last year.
While Unicycive Therapeutics beat the analyst consensus estimate for Q2 losses, the fact that losses increased compared to the same period last year could have a neutral impact on the stock. Investors may be encouraged by the better than expected results, but concerned about the increased losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100